Search Results

There are 661 results for: content related to: Pharmacokinetics of Intranasal Crushed OxyContin and Intravenous Oxycodone in Nondependent Prescription Opioid Abusers

  1. Clinical Pharmacology of Oxymorphone

    Pain Medicine

    Volume 10, Issue s1, April 2009, Pages: S3–S10, Howard S. Smith

    Version of Record online : 1 APR 2009, DOI: 10.1111/j.1526-4637.2009.00594.x

  2. You have free access to this content
    Oxymorphone active uptake at the blood–brain barrier and population modeling of its pharmacokinetic–pharmacodynamic relationship

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 9, September 2013, Pages: 3320–3331, Muhammad Waqas Sadiq, Emma Boström, Ron Keizer, Sven Björkman and Margareta Hammarlund-Udenaes

    Version of Record online : 5 MAR 2013, DOI: 10.1002/jps.23492

  3. Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans

    Addiction Biology

    Volume 21, Issue 1, January 2016, Pages: 146–158, Shanna Babalonis, Michelle R. Lofwall, Paul A. Nuzzo and Sharon L. Walsh

    Version of Record online : 31 JUL 2014, DOI: 10.1111/adb.12173

  4. Summary of Short-term and Long-term Oxymorphone Efficacy (Pain) Studies in Low Back Pain, Cancer Pain, Osteoarthritis, and Neuropathic Pain

    Pain Medicine

    Volume 10, Issue s1, April 2009, Pages: S11–S19, Michael J. Brennan

    Version of Record online : 1 APR 2009, DOI: 10.1111/j.1526-4637.2009.00595.x

  5. Sedative effects and serum drug concentrations of oxymorphone and metabolites after subcutaneous administration of a liposome-encapsulated formulation in dogs

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 27, Issue 5, October 2004, Pages: 369–372, L. J. Smith, L. Krugner-Higby, L. A. Trepanier, D. E. Flaska, V. Joers and T. D. Heath

    Version of Record online : 20 OCT 2004, DOI: 10.1111/j.1365-2885.2004.00582.x

  6. You have full text access to this OnlineOpen article
    The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical study

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 37, Issue 4, August 2014, Pages: 394–405, S. A. Martinez, M. G. Wilson, D. D. Linton, G. C. Newbound, K. J. Freise, T.-L. Lin and T. P. Clark

    Version of Record online : 18 DEC 2013, DOI: 10.1111/jvp.12096

  7. Oxymorphone and Opioid Rotation

    Pain Medicine

    Volume 10, Issue s1, April 2009, Pages: S39–S48, Joseph V. Pergolizzi Jr. and Robert B. Raffa

    Version of Record online : 1 APR 2009, DOI: 10.1111/j.1526-4637.2009.00598.x

  8. Pharmacokinetics of oxymorphone in cats

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 34, Issue 6, December 2011, Pages: 594–598, K. T. SIAO, B. H. PYPENDOP, S. D. STANLEY and J. E. ILKIW

    Version of Record online : 16 FEB 2011, DOI: 10.1111/j.1365-2885.2011.01271.x

  9. Effect of amantadine on oxymorphone-induced thermal antinociception in cats

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 35, Issue 2, April 2012, Pages: 169–174, K. T. SIAO, B. H. PYPENDOP, A. ESCOBAR, S. D. STANLEY and J. E. ILKIW

    Version of Record online : 28 APR 2011, DOI: 10.1111/j.1365-2885.2011.01305.x

  10. Efficacy of Oxymorphone Extended Release in Postsurgical Pain: A Randomized Clinical Trial in Knee Arthroplasty

    The Journal of Clinical Pharmacology

    Volume 44, Issue 7, July 2004, Pages: 767–776, Dr. Harry Ahdieh, Dr. Tina Ma, Dr. Najib Babul and Dr. David Lee

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270004266487

  11. Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways

    The Journal of Clinical Pharmacology

    Volume 45, Issue 3, March 2005, Pages: 337–345, Dr Michael Adams, Dr Henry J. Pieniaszek Jr, Dr Arnold R. Gammaitoni and Dr Harry Ahdieh

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270004271969

  12. Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial

    Pain Medicine

    Volume 6, Issue 5, September 2005, Pages: 357–366, Alan K. Matsumoto, Najib Babul and Harry Ahdieh

    Version of Record online : 21 OCT 2005, DOI: 10.1111/j.1526-4637.2005.00057.x

  13. You have free access to this content
    The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone

    British Journal of Pharmacology

    Volume 160, Issue 4, June 2010, Pages: 907–918, CF Samer, Y Daali, M Wagner, G Hopfgartner, CB Eap, MC Rebsamen, MF Rossier, D Hochstrasser, P Dayer and JA Desmeules

    Version of Record online : 24 MAY 2010, DOI: 10.1111/j.1476-5381.2010.00673.x

  14. Titration with Oxymorphone Extended Release to Achieve Effective Long-Term Pain Relief and Improve Tolerability in Opioid-Naive Patients with Moderate to Severe Pain

    Pain Medicine

    Volume 9, Issue 7, October 2008, Pages: 777–785, Richard Rauck, Tina Ma, Rosemary Kerwin and Harry Ahdieh

    Version of Record online : 7 DEC 2007, DOI: 10.1111/j.1526-4637.2007.00390.x

  15. Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs

    Veterinary Anaesthesia and Analgesia

    Volume 40, Issue 5, September 2013, Pages: 537–545, Lesley J Smith, Butch K Kukanich, Lisa A Krugner-Higby, Brynn H Schmidt and Timothy D Heath

    Version of Record online : 20 APR 2013, DOI: 10.1111/vaa.12042

  16. SEX DIFFERENCES IN THE PHARMACOKINETICS, OXIDATIVE METABOLISM AND ORAL BIOAVAILABILITY OF OXYCODONE IN THE SPRAGUE-DAWLEY RAT

    Clinical and Experimental Pharmacology and Physiology

    Volume 35, Issue 3, March 2008, Pages: 295–302, Samuel Chan, Stephen R Edwards, Bruce D Wyse and Maree T Smith

    Version of Record online : 31 OCT 2007, DOI: 10.1111/j.1440-1681.2007.04821.x

  17. Cancer Cachexia Raises the Plasma Concentration of Oxymorphone Through the Reduction of CYP3A But Not CYP2D6 in Oxycodone-Treated Patients

    The Journal of Clinical Pharmacology

    Volume 53, Issue 8, August 2013, Pages: 812–818, Takafumi Naito, Masaki Tashiro, Takuya Ishida, Kazunori Ohnishi and Junichi Kawakami

    Version of Record online : 3 JUN 2013, DOI: 10.1002/jcph.112

  18. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue

    Rapid Communications in Mass Spectrometry

    Volume 18, Issue 21, 15 November 2004, Pages: 2565–2576, Emma Boström, Britt Jansson, Margareta Hammarlund-Udenaes and Ulrika S. H. Simonsson

    Version of Record online : 4 OCT 2004, DOI: 10.1002/rcm.1658

  19. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites

    Clinical Pharmacology & Therapeutics

    Volume 79, Issue 5, May 2006, Pages: 461–479, Bojan Lalovic, Evan Kharasch, Christine Hoffer, Linda Risler, Lee-Yuan Liu-Chen and Danny D. Shen

    Version of Record online : 11 APR 2006, DOI: 10.1016/j.clpt.2006.01.009

  20. Pharmacokinetics and behavioral effects of oxymorphone after intravenous and subcutaneous administration to healthy dogs

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 31, Issue 6, December 2008, Pages: 580–583, B. KuKANICH, B. K. SCHMIDT, L. A. KRUGNER-HIGBY, S. TOERBER and L. J. SMITH

    Version of Record online : 17 AUG 2008, DOI: 10.1111/j.1365-2885.2008.00987.x